Brand-Name, Generics Deals Stifle Competition: FTC

Law360, New York (May 21, 2008, 12:00 AM EDT) -- Patent settlements in which drugmakers pay their generics rivals to keep generic competition off the market may stifle competition, according to a report from the U.S. Federal Trade Commission released on Tuesday.

"This report confirms that settlements with potentially anti-competitive arrangements continue to be prevalent," said FTC Chairman William E. Kovacic. "The commission remains committed to ensuring that brand and generic companies do not use such settlements as a way to deny consumers the benefits of competition."

There were 33 final settlements in pharmaceutical patent cases...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.